KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $562,180 | +156.0% | 58,378 | +79.7% | 0.00% | -75.0% |
| Q4 2022 | $219,578 | -89.8% | 32,482 | -78.2% | 0.00% | -90.2% |
| Q3 2022 | $2,160,000 | +7.4% | 148,867 | -27.1% | 0.04% | -25.5% |
| Q2 2022 | $2,011,000 | +112.6% | 204,338 | +218.2% | 0.06% | +120.0% |
| Q1 2022 | $946,000 | +368.3% | 64,210 | +285.0% | 0.02% | -44.4% |
| Q2 2020 | $202,000 | +27.0% | 16,676 | -19.8% | 0.04% | +28.6% |
| Q1 2020 | $159,000 | – | 20,800 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |